Ideal Cures launches new excipient; Pulmatrix moves forward with asthma inhalant;

 @DamianFierce: Prosonix says its new delivery platform makes combined APIs more effective: Story | Follow @DamianFierce

> Denmark's Veloxis Pharmaceuticals is planning to restructure and focus its efforts on LCP-Tacro, its organ-transplant-rejection treatment that uses a novel, once-daily formulation. Release

> Pulmatrix is touting positive clinical results for iCalm, its inhaled anti-inflammatory drug targeted at asthma and bronchitis patients. More

> Sigmoid Pharma has completed a Phase II trial of CyCol, an ulcerative colitis drug that uses a proprietary drug delivery tech that allows for oral vaccine administration. The company also pulled in $4 million in a financing round. News

> India's Ideal Cures has expanded its drug delivery options with the launch of a new excipient technology called Instanute DR. Story

> Researchers have been working on implantable drug delivery devices that can release doses by remote control, but, if adopted, what would the technology mean for medical privacy? Eliot Elwar of Digital Journal says the possibility is bad for patients. Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.